Literature DB >> 15505702

Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers.

Myrna B Dolovich1, Jolyon P Mitchell.   

Abstract

A new Canadian standard (CAN/CSA/Z264.1-02:2002) has been published with the purpose of helping to ensure the safety, efficacy and functionality of spacers and/or holding chambers. They are prescribed for use by spontaneously breathing patients for the treatment of various respiratory diseases where medication is delivered to the lungs using pressurized-metered dose inhalers. This consensus standard was developed with the support of pharmaceutical companies and manufacturers of spacers and holding chambers, and with the help of clinicians, retail pharmacists and representatives of patient advocate bodies associated with respiratory diseases and the dissemination of information related to the treatment and the delivery of inhaled medications. Advice was also sought from expert groups outside of Canada to ensure that the standard would be relevant internationally. Whereas monographs in the pharmaceutical compendia and guidance documents published by regulatory bodies provide information that is largely about the drug product and inhaler, this is the only standard whose focus is primarily on these add-on devices. The purpose of the present review is to highlight the main features of the standard for clinicians by describing its scope, the tests that are intended to assure the robustness of the construction of these devices, the type of testing that is specified to establish in vitro efficacy, and the recommendations for the marking and labelling of the device and its associated packaging. Manufacturers who test their products to this Canadian Standards Association standard will be able to provide performance information about add-on devices to the clinician, facilitating an informed decision when selecting devices for patients.

Entities:  

Mesh:

Year:  2004        PMID: 15505702     DOI: 10.1155/2004/497946

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  10 in total

1.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-05-18       Impact factor: 3.246

Review 2.  In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.

Authors:  Jolyon Mitchell; Steve Newman; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2007-12-21       Impact factor: 3.246

3.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

4.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

Review 5.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

6.  Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.

Authors:  Kaoru Toyama; Hidetoshi Furuie; Hitoshi Ishizuka
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing.

Authors:  Jolyon P Mitchell; Jason A Suggett
Journal:  AAPS PharmSciTech       Date:  2014-06-04       Impact factor: 3.246

8.  Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN).

Authors:  F Braido; N Scichilone; F Lavorini; O S Usmani; L Dubuske; L P Boulet; R Mosges; C Nunes; M Sanchez-Borges; I J Ansotegui; M Ebisawa; F Levi-Schaffer; L J Rosenwasser; J Bousquet; T Zuberbier; G Walter Canonica; A Cruz; A Yanez; A Yorgancioglu; D Deleanu; G Rodrigo; J Berstein; K Ohta; P Vichyanond; R Pawankar; S N Gonzalez-Diaz; S Nakajima; T Slavyanskaya; A Fink-Wagner; C Baez Loyola; D Ryan; G Passalacqua; J Celedon; J C Ivancevich; K Dobashi; M Zernotti; M Akdis; S Benjaponpitak; S Bonini; W Burks; L Caraballo; Z Awad El-Sayed; S Fineman; P Greenberger; E Hossny; J A Ortega-Martell; H Saito; M Tang; L Zhang
Journal:  World Allergy Organ J       Date:  2016-10-28       Impact factor: 4.084

Review 9.  Optimizing the Delivery of Inhaled Medication for Respiratory Patients: The Role of Valved Holding Chambers.

Authors:  R Andrew McIvor; Hollie M Devlin; Alan Kaplan
Journal:  Can Respir J       Date:  2018-04-04       Impact factor: 2.409

10.  Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN).

Authors:  F Braido; N Scichilone; F Lavorini; O S Usmani; L Dubuske; L P Boulet; R Mosges; C Nunes; M Sánchez-Borges; I J Ansotegui; M Ebisawa; F Levi-Schaffer; L J Rosenwasser; J Bousquet; T Zuberbier; G Walter Canonica
Journal:  Asthma Res Pract       Date:  2016-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.